NA Proactive news snapshot: Algernon Pharmaceuticals, 3 Mining, VR Resources, NexTech AR Solutions...

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) announced Thursday it has received ethics approval from a central institutional review board for US study sites for its multinational phase 2b/3 human study of NP-120 (Ifenprodil) as a potential therapeutic treatment for patients with the COVID-19 disease. Based on additional feedback from the US Food and Drug Administration, the company said it is planning to increase the size of the Phase 2b part of the study from 100 to 150 patients by adding a second treatment arm where patients receive a higher dose of Ifenprodil. Enrollment of the 1st patient for the Phase 2b/3 study is expected before the end of July 2020.  3 Mining Inc (CVE:OIII) is embracing virtual technology as it seeks to bring investors closer to its projects during the current restrictions caused by the pandemic. The group has teamed up with VRIFY Technology Inc to develop an interactive presentation of its properties in Val D’Or, Quebec. This includes virtual tours and 3D models of its Marban and Orenada deposits. "Through VRIFY, we’re bringing anyone who is interested directly into our properties where they can now visualize our innovative work in 3D and understand its potential value even better than before," Jose Vizquerra, the CEO of O3 Mining told investors in a statement. VR Resources Ltd (CVE:VRR) (OTCQB:VRRCF) said the TSX Venture Exchange had accepted for filing documentation about the property acquisition agreement dated June 22, 2020, whereby VR will acquire the Reveille property, a silver project in Nye county, Nevada. The firm will make an initial US$20,000 payment and issue 100,000 shares to the vendor on closing. An additional US$50,000 and 100,000 common shares are issuable should the company commence a diamond drill program. The vendor will retain a 3% net smelter return royalty on the property, of which up to 1.5% is purchasable by the company at any time. NexTech AR Solutions Corp (CSE:NTAR) (OTCQB:NEXCF) said partnering its technology with Fastly (NYSE:FSLY), which provides the edge cloud platform, had greatly enhanced user security for video streaming. Fastly's edge cloud platform provides a content delivery network, Internet security services, video and streaming services.  Nextech's InfernoAR is an advanced cloud-based AR Video Conferencing and Video Learning Experience Platform for events. Great Panther Mining Ltd (TSE:GPR) (NYSEAMERICAN:GPL)  said shareholders voted overwhelmingly in favour of all items of business at the AGM held on June 24. A total of 141,771,862 votes were cast, representing 45.38% of the shares as of the record date. Shareholders voted 95.28% in favour of setting the number of directors at nine, 95.89% in favour of appointing KPMG LLP as auditors, and 91.95% in favour of the amended and restated Omnibus Incentive Plan for three years. Great Panther is a gold and silver miner focused on the Americas. Gold Resource Corporation (NYSEAMERICAN:GORO), the Mexico and Nevada-focused miner, announced its monthly dividend of one-third of a cent per share for June 2020 payable on July 23 this year to shareholders of record as of July 13 this year. GORO has returned $114 million to its shareholders in consecutive monthly dividends since July 2010 and offers its shareholders the option to convert their cash dividends into physical gold and silver and take delivery. Empower Clinics Inc (CSE:CBDT) (OTCQB:EPWCF) announced Thursday that its search has begun for a facility in Vancouver to open a wellness clinic and headquarters for its Dosed Wellness psychedelics division. The company added that “significant progress” has been made in negotiations with Golden Teacher Films Inc to acquire 10% interest in certain royalty rights, intellectual property rights and interest in DOSED, an award-winning documentary about treating PTSD, anxiety and depression with psychedelics. NetCents Technology Inc (CSE:NC) (OTCQB:NTTCF), a cryptocurrency payments technologies company, announced Thursday it has made numerous enhancements to its system. The company said it has been running promotional test campaigns, both merchant direct and through Partners, to test the efficacy of various promotional incentives in driving merchant sign up, integration, and the processing of cryptocurrency transactions.  Through this testing, NetCents said it identified that due to the wide-range of merchant and partner industries, the ability to conduct partner-specific and varied promotions was key to the campaign's ongoing success. The Flowr Corporation (CVE:FLWR) (OTCMKTS:FLWPF) revealed Thursday that it has planted a variety of high THC strains on nearly 1 million square feet of land at its Portuguese cultivation facility. The Toronto-based cannabis company and its partner Terrace Global (CVE:TRCE) jointly operate the outdoor growing environment in Aljustrel. Flowr has shipped nearly 14,000 clones, including BC Pink Kush, BC Tahoe OG and BC Louis XII, from its Flowr Forest outdoor operation in Kelowna to Portugal. Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCMKTS:NSPDF) is expanding its e-commerce strategy and has struck a deal with boutique consultant Atlas 365 to establish an on-line ambassador program to promote the former's health food products. Particularly, the focus will be Naturally Splendid's Natera Sport ProCurc 30 product, which is an anti-inflammatory supplement launched in February this year. Atlas has hired Rozaay Management Inc for the project - a creative marketing and branding agency that works with many professional athletes, influencers across the NBA, MLB, NFL, MLS and CFL with a combined following of more than 100 million followers. Genprex Inc (NASDAQ:GNPX) announced that the United States Adopted Names (USAN) Council approved the generic name quaratusugene ozeplasmid, the company’s non-small cell lung cancer drug formerly known as Oncoprex. The USAN Council is the agency tasked with selecting simple, unique nonproprietary names for drug candidates. Genprex is also seeking proprietary approval for the brand name GPX-001. Obtaining both approvals is a necessary step in obtaining marketing approval. “The USAN’s adoption of our non-proprietary name is another step toward advancing our lead drug candidate, GPX-001 for non-small cell lung cancer, toward commercialization,” CEO Rodney Varner said in a statement. “We look forward to the adoption and rollout of a brand name for this drug as we continue to move along the development pathway.”